Abstract
Aging is a complex, multifactorial process driven by interconnected biological mechanisms collectively known as the hallmarks of aging, which contribute to functional decline and the onset of age-related diseases. High-mobility group box 1 (HMGB1), a nuclear DNA chaperone and damage-associated molecular pattern (DAMP), plays a pivotal role in regulating these hallmarks through its dual functions: preserving genomic stability within the nucleus and promoting inflammatory responses when released extracellularly. This review examines the multifaceted involvement of HMGB1 in key aging hallmarks, such as genomic instability, telomere attrition, mitochondrial dysfunction, and chronic inflammation. Emerging therapeutic approaches show potential in restoring genomic homeostasis, though significant challenges remain in translating these findings to human clinical settings.
Introduction: The Janus-Faced Protein
High-mobility group box 1 (HMGB1) is a highly conserved protein that functions as a biological "double agent" in the aging process. Its role is dictated entirely by its cellular location. Within the nucleus, HMGB1 acts as a DNA chaperone, safeguarding genomic stability and facilitating repair mechanisms like Base Excision Repair. However, when released into the extracellular space—either actively by stressed cells or passively via necrosis—it transforms into a potent Damage-Associated Molecular Pattern (DAMP). This review synthesizes findings from 90 peer-reviewed studies to map HMGB1’s influence across 11 of the 14 established hallmarks of aging, identifying it as a high-leverage therapeutic target.
Mechanistic Pathways and the Spatial Switch
The core of HMGB1's ambiguity lies in its translocation. Under normal conditions, it maintains chromatin integrity and telomere length. During age-related stress, it moves to the cytoplasm or extracellular environment, triggering inflammatory cascades that drive "inflammaging."
As illustrated in Figure 4, extracellular HMGB1 interacts with receptors such as TLR4 and RAGE, activating the NF-κB pathway and promoting the Senescence-Associated Secretory Phenotype (SASP). This transition acts as a mechanistic bridge between hallmarks; for example, it links mitochondrial dysfunction to chronic inflammation by mediating mitochondrial fission and the subsequent leakage of mtDNA into the cytoplasm.
Impact Across Hallmarks and Disease States
HMGB1 is implicated in a wide array of age-related pathologies, from neurodegeneration to metabolic disorders. Clinical data indicates that serum HMGB1 levels in healthy older adults are approximately 16% higher than in younger cohorts, correlating negatively with muscle strength and physical activity.
Figure 5 highlights how HMGB1 drives decline across different organ systems:
- Neurodegeneration: HMGB1 release triggered by Tau oligomers promotes astrocytic senescence in Alzheimer’s models.
- Osteoarthritis: It upregulates enzymes (MMP13, ADAMTS-5) that degrade the extracellular matrix in cartilage.
- Metabolic Health: Age-related gut dysbiosis triggers HMGB1 release, which travels via exosomes to the liver, promoting lipid accumulation and inflammation (NAFLD).
- Stem Cell Exhaustion: In mesenchymal stem cells, HMGB1 activates the NLRP3 inflammasome, inhibiting regenerative capacity.
Therapeutic Paradox and Future Directions
The essential nature of nuclear HMGB1 for DNA stability presents a therapeutic paradox: a total "knockout" of the protein is detrimental. Effective anti-aging strategies must be surgical, focusing on neutralizing only the extracellular fraction using antibodies or specific inhibitors like glycyrrhizin, or preventing the initial translocation from the nucleus.
While preclinical results are promising, human clinical validation remains sparse. Future research must address the "missing" hallmarks—deregulated nutrient sensing, loss of proteostasis, and psychosocial isolation—to fully understand HMGB1's potential as a universal biomarker for biological age and frailty.
Summary updated